Julio C. Palmaz

Learn More
My personal perspective about intravascular stents has been for the most part very positive. From its humble beginnings in the late '70s the stent become a major therapeutic resource and has achieved worldwide application. However, some disappointments in the last few years dampened my early unbridled enthusiasm. In my view, during its third decade of life(More)
BACKGROUND To evaluate the in vivo safety, biodistribution, and diagnostic accuracy of a monoclonal Fab' antibody (S12) that is specific for the platelet membrane glycoprotein (GMP-140) expressed during platelet activation at vascular injury sites, 11 peripheral percutaneous transluminal angioplasty (PTA) patients (age, 61 +/- 8 years) with severe vascular(More)
  • 1